Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (October 2019)
22 slides from Cynata Therapeutics's investor presentation, Oct 30, 2019
Slide 1: ASX Announcement: Cynata Corporate Presentation
ASX ANNOUNCEMENT 30 October 2019 For personal use only Cynata Corporate Presentation Melbourne, Australia; 30 October 2019: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), today released a presentation Cynata CEO, Dr Ross Macdonald, will use with inves
Slide 2: A Next Generation Stem Cell Therapeutics Company
For personal use only A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited October 2019
Slide 3: Important Information
Important Information For personal use only This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain
Slide 4: Phase II-ready biotech with scalable proprietary stem cell platform
Cynata Therapeutics is a Phase II-ready biotech with a highly scalable, proprietary platform for developing stem cell therapeutics For personal use only Our focus Financial information Share price (28-Oct-19) A$1.32 Utilise our proprietary CymerusTM platform technology to develop commercially scalab
Slide 5: 2019 Highlights: Driving Clinical and Commercial Success
2019 Highlights: Driving Clinical and Commercial Success Phase II GvHD trial Progressing Osteoarthritis For personal use only Fujifilm license funded by Fujifilm to Phase II trial Fujifilm exercised license option for Fujifilm to fund CYP-001 Advancing towards 448 patient CYP-001 in (GvH
Slide 6: Cymerus platform has potential applications across a wide range of diseases
Cynata's Cymerus platform has potential applications across a wide range of diseases For personal use only Key advantages of the platform: Graft vs Host Disease Crohn’s (GvHD) Disease Others Scalability & Consistency Fistula Coronary Artery Consistent product quality – Disease single donor overcom
Slide 7: Value inflection point following clear data and first commercial transaction
Value inflection point following clear data and first commercial transaction For personal use only Successful clinical study data Cynata’s current focus Demonstrating efficacy of our Commercialise technology via technology platform further licence agreements World-first allogeneic iPSC-derived cel
Slide 8: Cynata is targeting significant market opportunities
Cynata is targeting significant market opportunities For personal use only TARGET AREA TRIAL PHASE MARKET OPPORTUNITY Graft vs. Host Entering Clinical US $0.3bn1 Disease (GvHD) Phase II Critical limb ischemia Entering Clinical US $1.4bn2 (CLI) Phase II Entering Clinical Osteoarthritis Phase II US $1
Slide 9: Production and manufacturing process
Production and manufacturing process Our patented Cymerus platform enables the production of iPSC-derived cellular therapeutics from a single adult donor For personal use only iPSCs Cymerus technology platform MSCs Mature cells Induced Pluripotent Expansion of Precursor Precursor cell Differentiatio
Slide 10: GvHD clinical trial results: trial design
GvHD clinical trial results Clinical trial design and key implications of clinical trial results For personal use only Graft versus host disease (GVHD) is a condition where following a transplant the donor’s immune cells in the transplant What is (graft) make antibodies against the patient's tissues
Slide 11: GvHD clinical trial results: highly successful outcome
GvHD clinical trial results Highly successful outcome, with majority of patients reporting a Complete Response from a devastating disease For personal use only Phase I clinical trial data – all endpoints achieved1 Complete Response2 Overall Response3 Overall survival4 53% rate 87% rate ≥87% rate Pat
Slide 12: Fujifilm licensing agreement
Fujifilm licensing agreement Cynata is executing on a clear scientific and commercial vision and continually assesses pathways to optimise shareholder value Multiple options to create For personal use only shareholder value case study Build value in platform independently Exclusive global licence
Slide 13: Path to commercialisation
Path to commercialisation Strong clinical pipeline and program supports Cynata’s commercial objectives For personal use only New enhanced pipeline and clear pathway to commercialisation Direct path to market in Japan following Phase II US$300m1 GvHD Licensed to Fujifilm; Fujifilm responsible for
Slide 14: Pipeline and Catalysts
Pipeline and Catalysts Cynata has a large pipeline of indications with upcoming catalysts Today For personal use only H2 CY2018 H1 CY2019 H2 CY2019 Upcoming catalysts / status Graft vs Phase I trial Phase I trial Phase II trial expected to commence in CY2020 Host Disease completed Phase II ready lic
Slide 15: Globally experienced board and management team
Globally experienced board and management team For personal use only Dr Paul Wotton Dr Ross Macdonald Dr Stewart Washer Dr Geoff Brooke Mr Peter Webse Dr Kilian Kelly Chairman Managing Director / CEO Non-Exec Director Non-Exec Director Non-Exec Director Chief Operating Officer Company Secretary CE
Slide 16: Investment Summary
Investment Summary For personal use only Cymerus platform technology enables commercial-scale production of mesenchymal stem cells 1 Scalable, globally Fully patented process overcomes multiple issues with today’s on-market solutions applicable technology Value of platform to a range of diseas
Slide 17: Thank you for your attention
For personal use only Thank you for your attention Cynata Therapeutics Limited Contact details: Level 3 62 Lygon Street ross.macdonald@cynata.com Carlton Victoria 3053 www.cynata.com Australia
Slide 18: Appendix
For personal use only Appendix
Slide 19: Critical Limb Ischemia: Overview of Cynata-led Phase II program
Critical Limb Ischemia | Overview of Cynata-led Phase II program For personal use only 230,000 ~US$1.4B1 Addressable events per year Forecast annual global market sales Estimated market size Critical Limb MSC therapy for effective treatment of critical limb ischemia patients who are Ischemia (CLI)
Slide 20: Osteoarthritis: New Phase II program funded by NHMRC
Osteoarthritis | New Phase II program funded by National Health and Medical Research Council For personal use only 30,000,000 ~US$11.6B1 People in the USA affected by osteoarthritis Forecast global market opportunity by 2025 Estimated market size Assess the effect of Cymerus MSCs on clinical outco
Slide 21: Pre-clinical studies: Ongoing value-creating program
Pre-clinical studies | Ongoing value-creating program Pre-clinical studies are intended to provide a rational basis for investigating the potential safety and efficacy of For personal use only an experimental drug in particular disease indications Demonstrate • MSCs have already shown promising ther
Slide 22: Pre-clinical studies: Existing target areas
Pre-clinical studies | Existing target areas For personal use only Proof of Disease target Pre-clinical Global market Partner concept Key highlights area trials started opportunity* completed Study to commence to evaluate effectiveness of Cymerus MSCs in sheep with ARDS in US$2.5bn ARDS associatio
Cynata Therapeutics — Investor Presentation (October 2019) on 6ix